TED Ted Baker Plc

    
  Tepnel Life Sciences PLC
  14 October 2008
   


    
    Tepnel Life Sciences plc ('Tepnel' or 'the Company')

    TEPNEL EXPANDS GENETIC SERVICES PORTFOLIO WITH ADDITION OF ILLUMINA iScan RAPID READER

    Manchester, UK - 14th October 2008 Tepnel Life Sciences PLC (AIM: TED) today announced that it has expanded its molecular genetic
services offering through the addition of Illumina's iScan System, a next-generation scanner that provides researchers conducting genetic
variation studies with significantly greater throughput and application diversity.  This announcement marks the first anniversary of
Tepnel's new pharmaceutical services facility and makes Tepnel the first commercial provider of iScan services within the UK.

    Combined with Tepnel's established range of upstream and downstream genetic capabilities, the Company now offers a full suite of
complementary services from DNA extraction through to Bioinformatics.  Illumina's iScan platform supports both human and non-human
applications and is capable of generating up to 225 million genotypes per day.

    Tepnel also has a variety of other platforms and techniques for SNP-based investigations for both human and non-human research and
clinical applications.  This breadth of service enables Tepnel to provide a complete solution from DNA extraction through to SNP genotyping
and DNA sequencing, all undertaken in accordance with Good Laboratory Practice (GLP).

     "Tepnel can offer customers a broad portfolio of innovative genetic analysis assays some of which are supported on our new
high-throughput iScan reader," said David Scott, General Manager of Tepnel's Livingston facility. "This new addition to our service opens up
the possibility to our customers of whole genome association, focused content analysis, copy number variation analysis and, epigenetics on
both human and non-human samples, all within a regulatory compliant environment."

"Accelerating and expanding our molecular genetic services at this rapid pace reflects our commitment to the long-term strategy of building
Tepnel's market presence in the fast-growing sectors of pharmacogenomics/pharmacogenetics and genetic disease disposition testing," said
Allan Brown, Managing Director, Tepnel Research Products & Services.

    -End-

    For Further Information:

    Tepnel Life Sciences plc
    Carol Smith, Group Marketing Communications Manager
    0161 946 2200

    Capital MS&L
    Mary Clark or Joey Whineray
    Tel: +44 20 7307 5330

    Seymour Pierce Limited
    Mark Percy
    Tel: +44 20 7107 8000

    Notes to Editors

    About Tepnel Life Sciences plc
    Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences products and services Group with two divisions, Molecular
Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France with over
200 employees. Tepnel provides test kits, reagents and services to two highly synergistic markets, these being Molecular Diagnostics and
Biomedical Research. The Company's strategy has been to identify high growth niche opportunities within these multi-billion pound markets.
Tepnel focuses on these niche operations with internally developed products, patents, expertise and know-how as well as strategic
acquisitions, to develop a leadership position within these defined market segments. For more information please visit www.tepnel.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
NRAUSVWRWRRRARA

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024